Skip to main content
Log in

Dose-Dependent Effects of Intracoronary Verapamil on Systemic and Coronary Hemodynamics

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Calcium antagonists are used in interventional cardiology to prevent coronary vasoconstriction or to overcome the no-reflow phenomenon. The aim of the current study was to evaluate the dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. In 20 patients scheduled for routine coronary angiography, heart rate, blood pressure, and ECG recordings were recorded continuously and intracoronary flow velocity was obtained by intracoronary Doppler measurements in angiographically normal vessels. The cross-sectional area, measured by quantitative coronary angiography, allowed the calculation of coronary blood flow (CBF) and the coronary vascular resistance index (CVRI). Without premedication, increasing dosages of verapamil (0.01 mg, 0.1 mg, 1.0 mg, and 2.0 mg) were injected into the left coronary artery. Intracoronary verapamil administration led to a decrease in systemic blood pressure only after administration of 1.0 mg or 2.0 mg (change in mean arterial pressure: from 87.6 ± 14.6 mmHg to 80.1 ± 14.9 mmHg and 78.5 ± 13.9 mmHg, respectively; both P < 0.05) without a change in heart rate. Epicardial diameters of the left coronary artery increased only at dosages of 1.0 mg and 2.0 mg (from 2.14 ± 0.4 mm to 2.22 ± 0.3 mm, P < 0.01), whereas the coronary blood flow velocity increased significantly at the smallest dosage of 0.01 mg (from 19.9 ± 8.7 cm/s to 33.2 ± 14.9 cm/s, P < 0.001) and was further enhanced with increasing dosages. CBF increased and CVRI decreased at every dosage of verapamil compared with baseline values. CBF increased also after 0.1 mg (from 13.5 ± 6.5 mL/min to 19.5 ± 9.3 mL/min; P < 0.05), reaching a maximal effect after administration of 1.0 mg verapamil (26.3 ± 16.1 mL/min, P < 0.05). Application of 2.0 mg did not further increase CBF compared with 1.0 mg. Intracoronary application of verapamil leads to a decrease in systemic blood pressure at higher dosages, whereas heart rate remains unchanged at any dosage. The maximal increase in coronary blood flow and decrease in vascular resistance can be reached by administration of 1.0 mg verapamil into the left coronary artery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Intervention Cooperative Study in Elderly Hypertensive Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999;34:1129-1133.

    Google Scholar 

  2. Staessen JA, Thijs L, Fagard RH, et al. For the systolic hypertension in Europe (Syst-Eur) trial investigators. Calcium channel blockade and cardiovascular prognosis in the Euoropean trial on isolated systolic hypertension. Hypertension 1998;32:410-416.

    PubMed  Google Scholar 

  3. Behar S. Treatment of angina pectoris with calcium antagonists: Long-term follow-up. Cardiovasc Drugs Ther 1998;12:119-124.

    PubMed  Google Scholar 

  4. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm: Experience in 127 patients. N Engl J Med 1980;302:1269-1273.

    PubMed  Google Scholar 

  5. Stone PH. Calcium antagonists for Prinzmetal's variant angina, unstable angina and silent myocardial ischemia: Therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol 1987;59:101B-115B.

    PubMed  Google Scholar 

  6. Oldenburg O, Baumgart D, Schaar J, et al. Anti-ischemic effect of verapamil during an interventional revascularisation. Herz 1999;24:581-586.

    PubMed  Google Scholar 

  7. Piana RN, Paik GY, Monscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514-2518.

    PubMed  Google Scholar 

  8. Baumgart D, Haude M, Ge J, et al. Online integration of intravascular ultrasound images into angiographic images. Catheter Cardiovasc Diagn 1996;39:228-229.

    Google Scholar 

  9. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.

    PubMed  Google Scholar 

  10. Di Mario C, Meneveau N, Gil R, et al. Maximal blood flow velocity in severe coronary stenoses measured with a Doppler guidewire. Am J Cardiol 1993;71:54D-61D.

    PubMed  Google Scholar 

  11. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999;341:1447-1457.

    PubMed  Google Scholar 

  12. Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol 1986;7:916-924.

    PubMed  Google Scholar 

  13. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26:143-149.

    PubMed  Google Scholar 

  14. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987;75:1030-1036.

    PubMed  Google Scholar 

  15. Gloor HO, Urthaler F. Differential effect of verapamil isomers on sinus node and AV junctional region. Am J Physiol 1983;244:H80-H88.

    PubMed  Google Scholar 

  16. Parodi O, Neglia D, Palombo C, et al. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation 1997;96:864-873.

    PubMed  Google Scholar 

  17. Forman R, Kirk ES. Comparative effects of vasodilator drugs on large and small coronary resistance vessels in dog. Cardiovasc Res 1980;14:601-606.

    PubMed  Google Scholar 

  18. Caputo M, Nicolini F, Franciosi G, Gallotti R. Coronary artery spasm after coronary artery bypass grafting. Eur J Cardio-thorac Surg 1999;15:545-548.

    Google Scholar 

  19. Chouairi S, Carrie D, Puel J. Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Eur Heart J 1995;16:3-8.

    Google Scholar 

  20. Vahanian A, Lung B. Role of calcium channel blockers in reducing acute ischemia and preventing restenosis in PTCA. Drugs 1996;52:9-15.

    Google Scholar 

  21. Ishihara M, Sato H, Tateishi H, et al. Effects of various doses of intracoronary verapamil on coronary resistance vessels in humans. Jpn Circ J 1997;61:755-761.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oldenburg, O., Eggebrecht, H., Herrmann, J. et al. Dose-Dependent Effects of Intracoronary Verapamil on Systemic and Coronary Hemodynamics. Cardiovasc Drugs Ther 14, 651–655 (2000). https://doi.org/10.1023/A:1007823116491

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007823116491

Navigation